These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 28418859)

  • 21. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma.
    Moore HB; Culp-Hill R; Reisz JA; Lawson PJ; Sauaia A; Schulick RD; Del Chiaro M; Nydam TL; Moore EE; Hansen KC; D'Alessandro A
    Am J Surg; 2019 Dec; 218(6):1206-1212. PubMed ID: 31514959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein-metabolite panel for early-stage pancreatic cancer.
    Burki TK
    Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
    [No Abstract]   [Full Text] [Related]  

  • 24. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
    PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD
    Wang S; Chen J; Li H; Qi X; Liu X; Guo X
    Technol Cancer Res Treat; 2021; 20():15330338211045204. PubMed ID: 34605330
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
    Xue A; Scarlett CJ; Chung L; Butturini G; Scarpa A; Gandy R; Wilson SR; Baxter RC; Smith RC
    Br J Cancer; 2010 Jul; 103(3):391-400. PubMed ID: 20588270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.
    Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME
    J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.
    Chao DT; Shah NH; Zeh HJ; Bahary N; Whitcomb DC; Brand RE
    Pancreas; 2016 Feb; 45(2):228-33. PubMed ID: 26418902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma.
    Rho SY; Lee SG; Park M; Lee J; Lee SH; Hwang HK; Lee MJ; Paik YK; Lee WJ; Kang CM
    Sci Rep; 2019 Dec; 9(1):18634. PubMed ID: 31819109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.
    Zhong L; Zhang JP; Nuermaimaiti AG; Yunusi KX
    Eur Rev Med Pharmacol Sci; 2014; 18(23):3673-80. PubMed ID: 25535139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and comparison of serum biomarkers for diabetes mellitus and metabolic syndrome based on UPLC-Q-TOF/MS.
    Liu X; Gao X; Zhang R; Liu Z; Shen N; Di Y; Fang T; Li H; Tian F
    Clin Biochem; 2020 Aug; 82():40-50. PubMed ID: 32194037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer.
    Urayama S; Zou W; Brooks K; Tolstikov V
    Rapid Commun Mass Spectrom; 2010 Mar; 24(5):613-20. PubMed ID: 20143319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating correlations in the altered metabolic profiles of obese and diabetic subjects in a South Indian Asian population using an NMR-based metabolomic approach.
    Gogna N; Krishna M; Oommen AM; Dorai K
    Mol Biosyst; 2015 Feb; 11(2):595-606. PubMed ID: 25464928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer.
    Liang Q; Wang C; Li B
    Appl Biochem Biotechnol; 2015 Aug; 176(8):2170-84. PubMed ID: 26088916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
    Pang Y; Holmes MV; Chen Z; Kartsonaki C
    J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
    Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.